Nyra Medical

Executive Summary

Nyra Medical is a private medical device company headquartered in Menlo Park, California, founded in 2019 with a focus on transforming transcatheter mitral valve repair for functional mitral regurgitation (FMR). The company’s proprietary Cardiac Leaflet Enhancer (CARLEN) is a single-leaflet augmentation device designed to address limitations of current therapies, including TEER-eligible and anatomically challenging patients. CARLEN aims to expand the treatable population by providing a minimally invasive option that augments leaflet coaptation, potentially improving outcomes in FMR patients who are often elderly and high-risk for surgery. With the mitral valve repair market estimated at several billion dollars and current solutions only addressing a fraction of patients, Nyra Medical’s differentiated approach could capture significant share if clinical validation is achieved. The company is privately held and has not disclosed funding amounts or valuation, but its innovative technology targets a clear unmet need in structural heart disease, making it a compelling candidate for investment or partnership in the cardiovascular device space.

Upcoming Catalysts (preview)

• Q2 2027Initiation of pivotal clinical trial for CARLEN device45% success
• Q4 2026Series A funding round to support clinical development60% success
• Q1 2027First-in-human data readout or early feasibility study results55% success